Ustekinumab
Brand: Stelara
Immunomodulator
IL-12/IL-23 monoclonal antibody
Pharmacokinetics
| Half-life | 21 days |
| Clearance Route | reticuloendothelial |
| Active Metabolites | none |
| Notes | Clearance via IgG catabolism; weight-based dosing in Crohn’s/UC induction. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Infections (URTI), injection-site reactions, malignancy risk (rare), reversible posterior leukoencephalopathy syndrome (very rare)
Contraindications:
Active infections
Precautions:
Screen for TB; caution in malignancy; avoid live vaccines